Aditya Bardia, MD, MPH - Revolutionizing Treatment and Equity in HR+/HER2- Early Breast Cancer With CDK4/6 Inhibitors

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FHB865. CME/MOC/CC/NCPD/AAPA/IPCE credit will be available until January 25, 2025.Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAditya Bardia, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Daiichi Sankyo Inc./AstraZeneca; Foundation Medicine, Inc.; Genentech, Inc.; Immunomedics, Inc./Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Phillips Healthcare Corporation; Radius Health, Inc.; and Sanofi.Grant/Research Support from Daiichi Sankyo Inc./AstraZeneca; Genentech, Inc.; Immunomedics, Inc./Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Radius Health, Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.